Table 3 Treatment related answers
From: Management of anal cancer patients – a pattern of care analysis in German-speaking countries
University (A) vs. Non-university Clinic (B) vs. out-patient practice (C) | p-Value | |||
|---|---|---|---|---|
Total no of answers: 101 | A | B | C | |
RT modality | N(%) | N(%) | N(%) | |
3D | 0 (0) | 1 (3) | 2 (4) | |
IMRT | 4 (20) | 8 (22) | 12 (27) | |
Rotational IMRT (e.g. VMAT; RapidArc) | 14 (70) | 26 (72) | 31 (69) | |
Tomotherapy | 2 (10) | 1 (3) | 0 (0) | 0.43 |
Routine use of a SIB | ||||
Yes | 6 (30) | 15 (42) | 19 (42) | |
No | 14 (70) | 21 (58) | 26 (58) | 0.61 |
Use of alternative boost techniques | ||||
Electrons | 2 (10) | 6 (17) | 1 (2) | |
Brachytherapy | 4 (20) | 9 (25) | 2 (5) | |
No | 14 (70) | 21 (58) | 41 (93) | < 0.01 |
Standard CTx regime | ||||
5-FU/MMC | 19 (95) | 35 (97) | 41 (91) | |
Capecitabine/MMC | 1 (5) | 1 (3) | 4 (9) | 0.5 |
Adjuvant CTx | ||||
Yes; regularly | 0 (0) | 0 (0) | 1 (2) | |
Yes; sometimes | 4 (20) | 4 (11) | 3 (7) | |
No | 16 (80) | 32 (89) | 41 (91) | 0.45 |
Induction CTX | ||||
Yes; sometimes | 0 (0) | 1 (3) | 1 (2) | |
No | 20 (100) | 35 (97) | 44 (98) | 0.77 |
Standard CTx for HIV+ patients? | ||||
Yes | 18 (90) | 31 (88) | 38 (91) | |
w/ dose reduction | 2 (10) | 2 (6) | 1 (2) | |
No | 0 (0) | 2 (6) | 3 (7) | 0.57 |
Timepoint of response assessment | ||||
4–6 weeks after end of treatment | 0 (0) | 1 (3) | 1 (2) | |
6–8 weeks after end of treatment | 6 (30) | 4 (11) | 10 (22) | |
Up to 5 months after end of treatment | 14 (70) | 31 (86) | 34 (76) | 0.46 |
Evaluation of QoL/PROM | ||||
Yes | 4 (20) | 13 (37) | 10 (23) | |
No | 16 (80) | 22 (63) | 34 (77) | 0.26 |